Oncolytic virotherapy

Research output: Contribution to journalArticle

679 Citations (Scopus)

Abstract

Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral virus replication. The primary clinical milestone has been completion of accrual in a phase 3 trial of intratumoral herpes simplex virus therapy using talimogene laherparepvec for metastatic melanoma. Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to transiently suppress but then unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.

Original languageEnglish (US)
Pages (from-to)658-670
Number of pages13
JournalNature Biotechnology
Volume30
Issue number7
DOIs
StatePublished - Jul 2012

Fingerprint

Oncolytic Virotherapy
Viruses
Virus Replication
Oncolytic Viruses
Simplexvirus
Blood Vessels
Immune System
Immunity
Melanoma
Therapeutics
Immune system
Pharmaceutical Preparations
Neoplasms
Derivatives

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Biotechnology
  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

Oncolytic virotherapy. / Russell, Stephen J; Peng, Kah-Whye; Bell, John C.

In: Nature Biotechnology, Vol. 30, No. 7, 07.2012, p. 658-670.

Research output: Contribution to journalArticle

Russell, Stephen J ; Peng, Kah-Whye ; Bell, John C. / Oncolytic virotherapy. In: Nature Biotechnology. 2012 ; Vol. 30, No. 7. pp. 658-670.
@article{688e50dae5ad4d619b185209f324b0a5,
title = "Oncolytic virotherapy",
abstract = "Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral virus replication. The primary clinical milestone has been completion of accrual in a phase 3 trial of intratumoral herpes simplex virus therapy using talimogene laherparepvec for metastatic melanoma. Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to transiently suppress but then unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.",
author = "Russell, {Stephen J} and Kah-Whye Peng and Bell, {John C.}",
year = "2012",
month = "7",
doi = "10.1038/nbt.2287",
language = "English (US)",
volume = "30",
pages = "658--670",
journal = "Biotechnology",
issn = "1087-0156",
publisher = "Nature Publishing Group",
number = "7",

}

TY - JOUR

T1 - Oncolytic virotherapy

AU - Russell, Stephen J

AU - Peng, Kah-Whye

AU - Bell, John C.

PY - 2012/7

Y1 - 2012/7

N2 - Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral virus replication. The primary clinical milestone has been completion of accrual in a phase 3 trial of intratumoral herpes simplex virus therapy using talimogene laherparepvec for metastatic melanoma. Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to transiently suppress but then unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.

AB - Oncolytic virotherapy is an emerging treatment modality that uses replication-competent viruses to destroy cancers. Recent advances include preclinical proof of feasibility for a single-shot virotherapy cure, identification of drugs that accelerate intratumoral virus propagation, strategies to maximize the immunotherapeutic action of oncolytic viruses and clinical confirmation of a critical viremic threshold for vascular delivery and intratumoral virus replication. The primary clinical milestone has been completion of accrual in a phase 3 trial of intratumoral herpes simplex virus therapy using talimogene laherparepvec for metastatic melanoma. Key challenges for the field are to select 'winners' from a burgeoning number of oncolytic platforms and engineered derivatives, to transiently suppress but then unleash the power of the immune system to maximize both virus spread and anticancer immunity, to develop more meaningful preclinical virotherapy models and to manufacture viruses with orders-of-magnitude higher yields than is currently possible.

UR - http://www.scopus.com/inward/record.url?scp=84863653214&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863653214&partnerID=8YFLogxK

U2 - 10.1038/nbt.2287

DO - 10.1038/nbt.2287

M3 - Article

C2 - 22781695

AN - SCOPUS:84863653214

VL - 30

SP - 658

EP - 670

JO - Biotechnology

JF - Biotechnology

SN - 1087-0156

IS - 7

ER -